1011003440 (1004-12) 0810010067/J591; A Randomized Phase II Trial of 177-Lu Radio-labeled Monoclonal Antibody HuJ591 (177-Lu-J591) with Ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer after Local Therapy



Study Overview

The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.


Study Description

This research is being done because the standard treatments for prostate cancer that has returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal therapy are not curative. The study will assess the potential of the energy given off by the radioactive compound to kill cancer cell.

Additional Information:

Participants will not be paid for their participation.



Research Study Identifier: TX717
ClinicalTrials.gov Identifier: NCT1011003440 (1004-12)


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.